Ciclesonide

Generic Name: Ciclesonide

Brand Names: Alvesco, Omnaris, Zetonna

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₄O_₇

CAS Number: 126544-47-6

Unique Ingredient Identifier: S59502J185

Background: Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

Indication: For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Associated Conditions: Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Phase 2

Recruiting

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Niclosamide
Drug: Ciclesonide
Drug: Sotrovimab

First Posted Date: 2021-05-03

Last Posted Date: 2024-03-22

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 5000

Registration Number: NCT04870333

Locations: 🇬🇧
Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust, King's Lynn, United Kingdom
🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom

and more 42 locations

Inhaled Ciclesonide for Outpatients With COVID19

Phase 2

Terminated

Conditions: COVID 19

Interventions: Drug: Normal Saline intranasal and placebo inhaler
Drug: Ciclesonide
Drug: Ciclesonide nasal

First Posted Date: 2020-06-17

Last Posted Date: 2022-06-10

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 215

Registration Number: NCT04435795

Locations: 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦
McGill University Health Center, Montreal, Quebec, Canada
🇨🇦
Sunnybrook Hospital, Toronto, Ontario, Canada

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Ciclesonide

First Posted Date: 2020-05-06

Last Posted Date: 2023-02-09

Lead Sponsor: Covis Pharma S.à.r.l.

Target Recruit Count: 400

Registration Number: NCT04377711

Locations: 🇺🇸
University of Buffalo, Buffalo, New York, United States

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

Phase 2

Completed

Conditions: Corona Virus Infection
Sars-CoV2

Interventions: Drug: interferon β-1b
Dietary Supplement: Vitamins
Drug: Ciclesonide
Drug: Telmisartan

First Posted Date: 2020-04-22

Last Posted Date: 2022-02-04

Lead Sponsor: University Hospital, Bordeaux

Target Recruit Count: 412

Registration Number: NCT04356495

Locations: 🇫🇷
Bordeaux university Hospital, Bordeaux, France
🇫🇷
CNGE, Paris, France
🇫🇷
CHU de Montpellier, Montpellier, France

and more 4 locations

The Mannitol-Asthma-Ciclesonide-Study

Phase 4

Completed

Conditions: Asthma, Bronchial

Interventions: Drug: Ciclesonide

First Posted Date: 2019-02-15

Last Posted Date: 2019-07-25

Lead Sponsor: Cantonal Hosptal, Baselland

Target Recruit Count: 72

Registration Number: NCT03839433

Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis

Phase 3

Conditions: Chronic Rhinosinustis With Polyps

Interventions: Drug: Ciclesonide
Drug: Fluticasone

First Posted Date: 2016-01-28

Last Posted Date: 2016-01-28

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 32

Registration Number: NCT02665806

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BHT high
Drug: BI 54903 XX high
Drug: BI 54903 XX medium 2
Drug: BI 54903 XX low
Drug: BHT low
Drug: BHT medium
Drug: Ciclesonide
Drug: BI 54903 XX medium 1

First Posted Date: 2014-08-20

Last Posted Date: 2014-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02221375

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Ciclesonide Placebo
Drug: Ciclesonide

First Posted Date: 2014-06-04

Last Posted Date: 2017-02-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT02155881

Effect of High Dose Ciclesonide on Asthma Control

Phase 3

Completed

Conditions: Bronchial Asthma

Interventions: Drug: Ciclesonide

First Posted Date: 2011-10-19

Last Posted Date: 2017-02-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 520

Registration Number: NCT01455194

Omnaris Versus Levocetirizine Phase 4 Study

Phase 4

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: Ciclesonide & Levocetirizine
Drug: Ciclesonide
Drug: Levocetirizine

First Posted Date: 2011-09-08

Last Posted Date: 2012-09-06

Lead Sponsor: Handok Inc.

Target Recruit Count: 349

Registration Number: NCT01430260

Locations: 🇰🇷
handok pharmaceuticals co. LTD, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy